These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 34111559)

  • 1. Phosphorylation of TRIP13 at Y56 induces radiation resistance but sensitizes head and neck cancer to cetuximab.
    Banerjee R; Liu M; Bellile E; Schmitd LB; Goto M; Hutchinson MND; Singh P; Zhang S; Damodaran DPV; Nyati MK; Spector ME; Ward B; Wolf G; Casper K; Mierzwa M; D'Silva NJ
    Mol Ther; 2022 Jan; 30(1):468-484. PubMed ID: 34111559
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TRIP13 promotes error-prone nonhomologous end joining and induces chemoresistance in head and neck cancer.
    Banerjee R; Russo N; Liu M; Basrur V; Bellile E; Palanisamy N; Scanlon CS; van Tubergen E; Inglehart RC; Metwally T; Mani RS; Yocum A; Nyati MK; Castilho RM; Varambally S; Chinnaiyan AM; D'Silva NJ
    Nat Commun; 2014 Jul; 5():4527. PubMed ID: 25078033
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined EGFR1 and PARP1 Inhibition Enhances the Effect of Radiation in Head and Neck Squamous Cell Carcinoma Models.
    Frederick BA; Gupta R; Atilano-Roque A; Su TT; Raben D
    Radiat Res; 2020 Nov; 194(5):519-531. PubMed ID: 32936912
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thyroid receptor-interacting protein 13 and EGFR form a feedforward loop promoting glioblastoma growth.
    Hu L; Shen D; Liang D; Shi J; Song C; Jiang K; Menglin Ren ; Du S; Cheng W; Ma J; Li S; Bi X; Barr MP; Fang Z; Xu Q; Li W; Piao H; Meng S
    Cancer Lett; 2020 Nov; 493():156-166. PubMed ID: 32860853
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Upregulation of thyroid hormone receptor interactor 13 is associated with human hepatocellular carcinoma.
    Ju L; Li X; Shao J; Lu R; Wang Y; Bian Z
    Oncol Rep; 2018 Dec; 40(6):3794-3802. PubMed ID: 30542731
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased expression of TRIP13 drives the tumorigenesis of bladder cancer in association with the EGFR signaling pathway.
    Gao Y; Liu S; Guo Q; Zhang S; Zhao Y; Wang H; Li T; Gong Y; Wang Y; Zhang T; Dong Z; Bacich D; Chowdhury WH; Rodriguez R; Wang Z
    Int J Biol Sci; 2019; 15(7):1488-1499. PubMed ID: 31337978
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EGFR overexpression increases radiotherapy response in HPV-positive head and neck cancer through inhibition of DNA damage repair and HPV E6 downregulation.
    Alsahafi EN; Thavaraj S; Sarvestani N; Novoplansky O; Elkabets M; Ayaz B; Tavassoli M; Legends MF
    Cancer Lett; 2021 Feb; 498():80-97. PubMed ID: 33137407
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nicotine promotes lymph node metastasis and cetuximab resistance in head and neck squamous cell carcinoma.
    Shimizu R; Ibaragi S; Eguchi T; Kuwajima D; Kodama S; Nishioka T; Okui T; Obata K; Takabatake K; Kawai H; Ono K; Okamoto K; Nagatsuka H; Sasaki A
    Int J Oncol; 2019 Jan; 54(1):283-294. PubMed ID: 30431077
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting TRIP13 for overcoming anticancer drug resistance (Review).
    Zhao L; Ye S; Jing S; Gao YJ; He T
    Oncol Rep; 2023 Nov; 50(5):. PubMed ID: 37800638
    [TBL] [Abstract][Full Text] [Related]  

  • 10. p31
    Sarangi P; Clairmont CS; Galli LD; Moreau LA; D'Andrea AD
    Proc Natl Acad Sci U S A; 2020 Oct; 117(43):26795-26803. PubMed ID: 33051298
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cetuximab sensitivity of head and neck squamous cell carcinoma xenografts is associated with treatment-induced reduction in EGFR, pEGFR, and pSrc.
    Jedlinski A; Garvin S; Johansson AC; Edqvist PH; Ponten F; Roberg K
    J Oral Pathol Med; 2017 Oct; 46(9):717-724. PubMed ID: 28036101
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cetuximab Resistance in Head and Neck Cancer Is Mediated by EGFR-K
    Braig F; Kriegs M; Voigtlaender M; Habel B; Grob T; Biskup K; Blanchard V; Sack M; Thalhammer A; Ben Batalla I; Braren I; Laban S; Danielczyk A; Goletz S; Jakubowicz E; Märkl B; Trepel M; Knecht R; Riecken K; Fehse B; Loges S; Bokemeyer C; Binder M
    Cancer Res; 2017 Mar; 77(5):1188-1199. PubMed ID: 28031227
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of EGFR or IGF-1R signaling enhances radiation response in head and neck cancer models but concurrent inhibition has no added benefit.
    Raju U; Molkentine DP; Valdecanas DR; Deorukhkar A; Mason KA; Buchholz TA; Meyn RE; Ang KK; Skinner H
    Cancer Med; 2015 Jan; 4(1):65-74. PubMed ID: 25355701
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dasatinib blocks cetuximab- and radiation-induced nuclear translocation of the epidermal growth factor receptor in head and neck squamous cell carcinoma.
    Li C; Iida M; Dunn EF; Wheeler DL
    Radiother Oncol; 2010 Nov; 97(2):330-7. PubMed ID: 20667610
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insulin-like growth factor 1 receptor mediated tyrosine 845 phosphorylation of epidermal growth factor receptor in the presence of monoclonal antibody cetuximab.
    Iyer G; Price J; Bourgeois S; Armstrong E; Huang S; Harari PM
    BMC Cancer; 2016 Oct; 16(1):773. PubMed ID: 27716204
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dacomitinib, an irreversible Pan-ErbB inhibitor significantly abrogates growth in head and neck cancer models that exhibit low response to cetuximab.
    Ather F; Hamidi H; Fejzo MS; Letrent S; Finn RS; Kabbinavar F; Head C; Wong SG
    PLoS One; 2013; 8(2):e56112. PubMed ID: 23405260
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TRIP13 promotes the proliferation and invasion of lung cancer cells via the Wnt signaling pathway and epithelial-mesenchymal transition.
    Li ZH; Lei L; Fei LR; Huang WJ; Zheng YW; Yang MQ; Wang Z; Liu CC; Xu HT
    J Mol Histol; 2021 Feb; 52(1):11-20. PubMed ID: 33128167
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cetuximab augments cytotoxicity with poly (adp-ribose) polymerase inhibition in head and neck cancer.
    Nowsheen S; Bonner JA; Lobuglio AF; Trummell H; Whitley AC; Dobelbower MC; Yang ES
    PLoS One; 2011; 6(8):e24148. PubMed ID: 21912620
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of GRP78 abrogates radioresistance in oropharyngeal carcinoma cells after EGFR inhibition by cetuximab.
    Sun C; Han C; Jiang Y; Han N; Zhang M; Li G; Qiao Q
    PLoS One; 2017; 12(12):e0188932. PubMed ID: 29232380
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elevated TRIP13 drives the AKT/mTOR pathway to induce the progression of hepatocellular carcinoma via interacting with ACTN4.
    Zhu MX; Wei CY; Zhang PF; Gao DM; Chen J; Zhao Y; Dong SS; Liu BB
    J Exp Clin Cancer Res; 2019 Sep; 38(1):409. PubMed ID: 31533816
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.